Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma : LLong-term results of a phase III randomized trial;Radiotherapie versus Radiochemotherapie mit Cisplatin für 5 Tage bei fortgeschrittenem Zervixkarzinom. Langzeitergebnisse einer randomisierten Phase-III-Studie

Strahlentherapie und Onkologie

Volumn 185, Issue 3, 2009, Pages 177-183

  Nagy, Viorica ^a,b   Coza, Ovidiu ^a,b   Ordeanu, Claudia ^a   Třailǎ, Alexandru ^a   Rancea, Alin ^a,b   Todor, Nicolae ^a   Ghilezan, Nicolae ^a,b  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cervical cancer; Radiochemotherapy; Surgery

Indexed keywords

CISPLATIN;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PELVIS; PHASE 3 CLINICAL TRIAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA; X RAY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; GERMANY; HUMANS; INCIDENCE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 63449127514     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-009-1893-z     Document Type: Article

References (23)

1. I. Barillot J.C. Horiot J. Pigneux 1997 Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors Int J Radiat Oncol Biol Phys 38 969 78
2. Chiricuta I, Munteanu S, Risca M, et al. Cancerul colului uterin. Cluj: Dacia, 1972.
3. K. Dellas M. Bache S.U. Pigorsch 2008 Prognostic impact of HIF-1α expression in patients with definitive radiotherapy for cervical cancer Strahlenther Onkol 184 169 74
4. J. Dunst G. Haensgen 2001 Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy Strahlenther Onkol 177 635 40
5. P.J. Eifel 1994 Problems with the clinical staging of carcinoma of the cervix Semin Radiat Oncol 4 1 8
6. M.H. Einstein A.P. Novetsky M. Garg 2007 Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer Cancer 109 48 53
7. J. Füller D. Guderian C. Köhler 2008 Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer Strahlenther Onkol 184 206 11
8. G. Hänsgen T. Kuhnt S. Pigorsch 2002 Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation Results of a pilot study. Strahlenther Onkol 178 71 7
9. G. Hänsgen K. Richter R. Gerlach 2005 Prognostic factors after surgery and adjuvant radiotherapy in cervical cancers. A retrospective analysis of 298 patients after surgery and adjuvant radiotherapy Strahlenther Onkol 181 285 92
10. H.M. Key B.N. Bundy F.B. Stehman 1999 Cisplatin radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1154 61
11. S. Marnitz C. Köhler C. Roth 2008 Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging Strahlenther Onkol 183 473 8
12. M. Morris P.J. Eifel J. Lu 1999 Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1137 43
13. M. Nagy 2003 Changes in natural history of cervical cancer through concomitant radiochemotherapy Radioter Oncol Med 9 21 6
14. R. Pearcey M. Brundage P. Douin 2002 Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix J Clin Oncol 20 966 72
15. C.A. Perez H.M. Camel R.R. Kuske 1986 Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience Gynecol Oncol 23 127 40
16. W.A. Peters P.Y. Liu R.J. Barrett 2000 Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 1606 13
17. P.G. Rose S. Ali E. Watkins 2007 Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2804 10
18. P.G. Rose B.N. Bundy E.B. Watkins 1999 Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1144 53
19. F. Sterzing C. Grehn J. Dinkel 2007 Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy Strahlenther Onkol 183 487 9
20. O. Suteu N. Ghilezan N. Todor 2001 Uterine cervix cancer epidemiology in Romania 1959-1999 Radioter Oncol Med 7 40 51
21. C.J. Tseng C.T. Chang C.H. Lai 1997 A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix Gynecol Oncol 66 52 8
22. H. Varveris S. Kachris M. Mazonakis 2006 Phase I/II trial of external irradiation plus medium-dose brachytherapy given concurrently to liposomal doxorubicin and cisplatin for advanced uterine cervix carcinoma Strahlenther Onkol 182 125 34
23. C.W. Whitney W. Sause B.N. Bundy 1999 Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes Gynecologic Oncology Group and Southwest Group study. J Clin Oncol 17 1339 48